Press release
Focal Segmental Glomerulosclerosis Market Expected to rise, 2034 | Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara
Focal Segmental Glomerulosclerosis Market 2034
The Focal Segmental Glomerulosclerosis market report [https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Focal Segmental Glomerulosclerosis market size, share, Focal Segmental Glomerulosclerosis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Focal Segmental Glomerulosclerosis market size growth forward.
Some of the key highlights from the Focal Segmental Glomerulosclerosis Market Insights Report:
*
Several key pharmaceutical companies, including Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara, ZyVersa, Boehringer Ingelheim, Eli Lilly and Company, and others, are developing novel products to improve the Focal Segmental Glomerulosclerosis treatment outlook.
*
The Focal Segmental Glomerulosclerosis market was valued at around USD 734 million in 2022 and is expected to expand at a substantial compound annual growth rate (CAGR) throughout the forecast period (2020-2034).
*
In March 2024, ZyVersa Therapeutics achieved a major milestone by launching its first-in-human clinical trial for VAR 200. The trial is designed to confirm the promising preclinical results seen in three different animal models of kidney disease, including diabetic kidney disease, focal segmental glomerulosclerosis, and Alport syndrome, and assess their relevance for patients with kidney disease.
*
In 2022, the United States accounted for around 34% of the total Focal Segmental Glomerulosclerosis (FSGS) drug market, with significant growth expected during the forecast period.
*
The combined market of the EU4 and the UK reached an estimated USD 147 million in 2022, and is projected to grow at a strong compound annual growth rate (CAGR). Within Europe, France held the largest market share in 2022, followed by Germany.
*
The Focal Segmental Glomerulosclerosis (FSGS) market is expected to experience growth throughout the forecast period (2023-2034), driven by the approval of promising new drugs.
*
According to DelveInsight's analysis, the United States accounts for the highest proportion of diagnosed FSGS cases, representing 46.96% of the total in the 7MM. Japan follows with approximately 14.83% of diagnosed FSGS cases in 2022. Our analysis suggests that men are more commonly affected by FSGS across the 7MM, a disparity potentially influenced by factors such as hormones, genetics, and environment. The FSGS market in the 7MM is largely driven by therapies like Statins, Ezetimibe/Bempedoic Acid and their combinations, along with PCSK9 inhibitors, which collectively generated nearly USD 23 million in 2022.
*
As per DelveInsight analysis, the Focal Segmental Glomerulosclerosis market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Focal Segmental Glomerulosclerosis Market Landscape [https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Focal Segmental Glomerulosclerosis Overview
Focal Segmental Glomerulosclerosis (FSGS) is a kidney disorder characterized by scarring (sclerosis) in specific segments (focal) of the glomeruli, the kidney's filtering units. The glomeruli play a crucial role in producing urine by filtering waste and excess fluid from the blood. Symptoms of FSGS include proteinuria (large amounts of protein in the urine), edema (swelling, particularly around the eyes, hands, feet, and abdomen, which leads to sudden weight gain), low blood albumin levels, high cholesterol in some cases, high blood pressure, and an increased tendency to develop blood clots.
Do you know the treatment paradigms for different countries? Download our Focal Segmental Glomerulosclerosis Market Sample Report [https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Focal Segmental Glomerulosclerosis Epidemiology Segmentation
DelveInsight's Focal Segmental Glomerulosclerosis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Focal Segmental Glomerulosclerosis historical patient pools and forecasted Focal Segmental Glomerulosclerosis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Focal Segmental Glomerulosclerosis Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
*
Focal Segmental Glomerulosclerosis Prevalence
*
Age-Specific Focal Segmental Glomerulosclerosis Prevalence
*
Gender-Specific Focal Segmental Glomerulosclerosis Prevalence
*
Diagnosed and Treatable Cases of Focal Segmental Glomerulosclerosis
Visit for more @ Focal Segmental Glomerulosclerosis Epidemiological Insights [https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Focal Segmental Glomerulosclerosis Market Outlook
Focal Segmental Glomerulosclerosis (FSGS) includes a range of conditions such as coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular disease, all of which are linked to atherosclerosis. FSGS is shaped by genetic factors, lifestyle choices, and existing comorbidities. Treatment approaches vary based on the severity of the condition, with the goal of managing FSGS. Initial treatment focuses on lifestyle changes, including stress management, regular exercise, a balanced diet, and smoking cessation. A comprehensive review of their impact on patient outcomes emphasizes how these changes can complement pharmaceutical treatments and effectively reduce cardiovascular risk factors.
Focal Segmental Glomerulosclerosis Marketed Drugs
*
LEQVIO (Inclisiran): Novartis Pharmaceuticals Corporation
Focal Segmental Glomerulosclerosis Emerging Drugs
*
Olpasiran (AMG 890): Amgen Inc.
Focal Segmental Glomerulosclerosis Key Companies
*
Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara, ZyVersa, Boehringer Ingelheim, Eli Lilly and Company, and others
For more information, visit Focal Segmental Glomerulosclerosis Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Scope of the Focal Segmental Glomerulosclerosis Market Report:
*
11 Years Forecast
*
7MM Coverage
*
Descriptive overview of Focal Segmental Glomerulosclerosis, causes, signs and symptoms, diagnosis, treatment
*
Comprehensive insight into Focal Segmental Glomerulosclerosis epidemiology in the 7MM
*
Focal Segmental Glomerulosclerosis marketed and emerging therapies
*
Focal Segmental Glomerulosclerosis companies
*
Focal Segmental Glomerulosclerosis market drivers and barriers
Table of Contents:
1 Focal Segmental Glomerulosclerosis Market Key Comprehensive Insights
2 Focal Segmental Glomerulosclerosis Market Report Introduction
3 Competitive Intelligence Analysis for Focal Segmental Glomerulosclerosis
4 Focal Segmental Glomerulosclerosis Market Analysis Overview at a Glance
5 Executive Summary of Focal Segmental Glomerulosclerosis
6 Focal Segmental Glomerulosclerosis Epidemiology and Market Methodology
7 Focal Segmental Glomerulosclerosis Epidemiology and Patient Population
8 Focal Segmental Glomerulosclerosis Patient Journey
9 Focal Segmental Glomerulosclerosis Treatment Algorithm, Focal Segmental Glomerulosclerosis Current Treatment, and Medical Practices
10 Key Endpoints in Focal Segmental Glomerulosclerosis Clinical Trials
11 Focal Segmental Glomerulosclerosis Marketed Therapies
12 Focal Segmental Glomerulosclerosis Emerging Therapies
13 Focal Segmental Glomerulosclerosis: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Focal Segmental Glomerulosclerosis
16 Focal Segmental Glomerulosclerosis Market Key Opinion Leaders Reviews
18 Focal Segmental Glomerulosclerosis Market Drivers
19 Focal Segmental Glomerulosclerosis Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Focal Segmental Glomerulosclerosis Epidemiology 2034
DelveInsight's "Focal Segmental Glomerulosclerosis - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Focal Segmental Glomerulosclerosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Focal Segmental Glomerulosclerosis Pipeline 2024
"Focal Segmental Glomerulosclerosis Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Focal Segmental Glomerulosclerosis market. A detailed picture of the Focal Segmental Glomerulosclerosis pipeline landscape is provided, which includes the disease overview and Focal Segmental Glomerulosclerosis treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=focal-segmental-glomerulosclerosis-market-expected-to-rise-2034-travere-therapeutics-dimerix-goldfinch-bio-vertex-pharmaceuticals-pfizer-chinook-therapeutics-inc-genentech-complexa-imara]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Focal Segmental Glomerulosclerosis Market Expected to rise, 2034 | Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara here
News-ID: 3852132 • Views: …
More Releases from ABNewswire
What are the most effective medical therapies for managing excess body mass? Reg …
Cape Coral healthcare providers report breakthrough success using FDA-approved GLP-1 medications for weight management, with Premier Wellness Florida leading comprehensive treatment programs combining pharmaceuticals with holistic wellness support.
Cape Coral, FL - Recent clinical developments in medical weight management have prompted Southwest Florida healthcare providers to report significant patient success rates with FDA-approved medications and comprehensive treatment protocols. Premier Wellness Florida, operating from its Del Prado Boulevard facility, has documented patient…
Winkler Kurtz LLP - Long Island Lawyers Port Jefferson Station Injury Attorney O …
Winkler Kurtz LLP is a leading Long Island law firm specializing in personal injury cases such as car accidents, slip and falls, and medical malpractice. Offering decades of local experience, the firm provides compassionate support and skilled legal advocacy to help injury victims secure justice and compensation. With free consultations and a contingency fee policy, Winkler Kurtz LLP ensures quality legal help is available to all Long Islanders in need.
When…
How to Pick the Best Online Chemistry Tutoring Platform
Image: https://www.abnewswire.com/upload/2025/10/814f4b38d9855ce5fcc0509bfebaa240.jpg
Choosing the right chemistry tutoring platform can make the difference between academic success and continued struggles with complex reactions and molecular structures. With students increasingly turning to digital solutions for personalized learning support, the online chemistry tutoring market has exploded with options promising everything from AI-powered progress tracking to virtual lab experiences that transform how learners approach this challenging subject.
Essential Platform Features for Effective Online Chemistry Tutoring
Modern chemistry tutoring…
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
More Releases for Focal
Focal Epilepsy Market New Product Development & Latest Trends
Introduction
Focal epilepsy, the most common form of epilepsy worldwide, originates in specific regions of the brain and often presents with partial seizures. Affecting millions of people globally, focal epilepsy remains a pressing neurological challenge with significant clinical and economic impact. Increasing diagnosis rates, technological advances in imaging and neurostimulation, and new pharmacological approaches are fueling rapid changes in the treatment landscape.
As healthcare systems place greater emphasis on effective long-term management…
Focal Segmental Glomerulosclerosis Market Size Report 2024
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Focal Segmental Glomerulosclerosis Drugs Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $22.41 billion In…
3D FOCAL LINES SPATULA TECHNOLOGY for SYGMALIFT
Focal Ultrasounds in three-dimensional (3D) technology expand to the Face Lifting and V Facing. This innovation is able to treat volume that contains every conceivable plane (X, Y, Z angles) within the region of interest such as Double Chin or Cheeks.
While there is no doubt that there are advantages to volume treatment in 2.5 Seconds only, it delivers more power and add clinical benefit to target submental and jawlines…
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics - Pipeline Analysis 2018
Focal segmental glomerulosclerosis (FSGS) is a glomerular disease, which is characterized by scarring or sclerosis in the kidney. Scarring damages the limited number of glomeruli in the initial stages. It is more common in males than in females, anad is very common in African American population.
Download the sample report @ https://www.pharmaproff.com/request-sample/1090
FSGS can be caused by many diseases like diabetes, sickle cell disease, and HIV infection. It is categorized into two…
Focal Segmental Glomerulosclerosis (FSGS) Market Report 2018: Segmentation by Di …
Global Focal Segmental Glomerulosclerosis (FSGS) market research report provides company profile for Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., AstraZeneca plc., Pfizer, Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth…
Africa Energy Week – Three Different Focal Points, One Conference
Africa’s development in oil and gas has significantly increased over the last few years; Ghana’s Jubilee field, first discovered in 2007, is now producing 70,000 barrels a day and may climb to 120,000 by the end of the year. With much of its oil for export, the country’s economic growth is climbing at a rapid rate, and many are looking to follow suit. Local content has since been a hot…
